Clotilde Costa,
Translational Medical Oncology Group,
Joint Unit Roche-Chus, Oncomet, Universitary Cinical Hospital of Santiago de Compostela
She obtained her Biology Degree at Vigo University, then she developed her Ph.D. in Molecular Oncology at CIEMAT (Madrid) focused on the study of the cell cycle genes in squamous cell carcinomas. In 2013 she joined Translational Medical Oncology Group at Santiago de Compostela to work in the study of metastasis through Liquid Biopsy. Since 2015 she is responsible for the Liquid Biopsy Line at the Joint Unit Roche-Chus sited at the Clinical Hospital of Santiago de Compostela. She is focused on the identification of biomarkers and understanding the metastatic process biology of breast cancer through the study of circulating tumor entities.
Red Blood Cells Protein Profile Is Modified in Breast Cancer Patients
Tuesday, 20 June 2023 at 09:00
Add to Calendar ▼2023-06-20 09:00:002023-06-20 10:00:00Europe/LondonRed Blood Cells Protein Profile Is Modified in Breast Cancer PatientsCirculating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Metastasis is the primary cause of death for most breast cancer (BC) patients who succumb to the disease. During the hematogenous dissemination, circulating tumor cells interact with different blood components. Thus, there are microenvironmental and systemic processes contributing to cancer regulation. We have recently published that red blood cells (RBCs) that accompany circulating tumor cells have prognostic value in metastatic BC patients. RBC alterations are related to several diseases. Although the principal known role is gas transport, it has been recently assigned additional functions as regulatory cells on circulation. Hence, to explore their potential contribution to tumor progression, we characterized the proteomic composition of RBCs from 53 BC patients from stages I to III and IV, compared with 33 cancer-free controls. In this work, we observed that RBCs from BC patients showed a different proteomic profile compared to cancer-free controls and between different tumor stages. The differential proteins were mainly related to extracellular components, proteasome, and metabolism. Embryonic hemoglobins, not expected in adults’ RBCs, were detected in BC patients. Besides, lysosome-associated membrane glycoprotein 2 emerge as a new RBCs marker with diagnostic and prognostic potential for metastatic BC patients. Seemingly, RBCs are acquiring modifications in their proteomic composition that probably represents the systemic cancer disease, conditioned by the tumor microenvironment.
Add to Calendar ▼2023-06-19 00:00:002023-06-20 00:00:00Europe/LondonCirculating Biomarkers and Extracellular Vesicles Europe 2023Circulating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-06-20 09:00:002023-06-20 10:00:00Europe/LondonRed Blood Cells Protein Profile Is Modified in Breast Cancer PatientsCirculating Biomarkers and Extracellular Vesicles Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
